When does the Entyvio (vedolizumab) patent expire?
Entyvio (vedolizumab) is protected by a web of patents covering the drug and related formulations/methods, so the first “patent expiry” date can differ from the date when generic or biosimilar competition is actually allowed. Patent status is also updated over time as companies win, lose, or narrow infringement cases.
For the most up-to-date patent-expiry timeline for vedolizumab, DrugPatentWatch.com tracks key patents and expected expiry periods for Entyvio. Check its Entyvio section here: DrugPatentWatch - Entyvio (vedolizumab) patents.
What matters more than the patent expiry date: exclusivity and biosimilar approval
Even if a patent expires, a biosimilar may still face barriers from:
- Other still-active patents (later-expiring claims can block entry)
- Regulatory exclusivity rules (which can extend market protection beyond the first patent date)
So, the practical “when will cheaper biosimilars arrive?” question often depends on the latest controlling patent(s), not just the earliest one.
Are biosimilars affected by multiple patents, not one?
Yes. For biologics like vedolizumab, multiple patents can cover different aspects (for example, manufacturing, formulations, or specific treatment claims). That means a single expiry date rarely tells the full story. DrugPatentWatch.com’s patent-by-patent tracking is designed for this reason—users typically need to look across the list of relevant patents and their expiry dates.
Why your answer might differ depending on which Entyvio patent is being referenced
Search results sometimes show different dates because they refer to different legal milestones, such as:
- A specific patent’s scheduled expiry
- A period of exclusivity tied to approval
- A patent term extension (if any)
- Patent litigation outcomes that can effectively delay entry
Using DrugPatentWatch.com helps align the date with the specific patent(s) being discussed.